Nitrile exam gloves, one of the highest-volume consumables in any healthcare facility, have been hit particularly hard by the tariff escalation on Chinese-manufactured medical goods that took effect at the start of 2026. With duties on the category effectively doubling to 100%, and additional forced-labor-related tariffs layered on top for certain manufacturers, facility glove budgets are absorbing one of the sharpest single-category cost increases in recent memory.
Why Gloves Are Especially Exposed
Unlike many medical device categories with more diversified global manufacturing, nitrile glove production remains heavily concentrated in a handful of Southeast Asian countries, with China historically supplying a significant share of U.S. hospital demand either directly or through intermediary distributors. That concentration leaves the category with fewer readily available lower-tariff alternatives than facilities might assume.
What Buyers Are Doing
- Shifting volume toward Malaysian and Thai manufacturers, which face meaningfully lower duty rates and have expanded capacity in response to the tariff differential
- Renegotiating multi-year contracts that locked in pricing before the tariff change, where contract language allows for reopening terms under substantial cost basis shifts
- Evaluating vinyl and other glove material alternatives for lower-risk, non-sterile applications where nitrile's superior barrier properties aren't clinically essential
What This Means for Budgets Going Forward
Facilities should expect glove line-item costs to remain elevated relative to pre-2026 baselines even after supply chains fully adjust, since the tariff increase reflects a durable policy shift rather than a temporary market disruption. Building the higher cost basis into multi-year budget planning now avoids repeated painful renegotiation later.
Facilities managing glove sourcing can review current options across Healix Medical Supply's gloves catalog.
